A new target for diagnosis and treatment of CNS disorders: Agmatinergic system

Current Medicinal Chemistry

Volumn 19, Issue 30, 2012, Pages 5116-5121

  Uzbay, T ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Agmatine; Central disorders; Central nervous system (CNS); Imidazoline receptors; NMDA receptors; Pharmacology; Polyamines; Schizophrenia

Indexed keywords

2 (2 IMIDAZOLIN 2 YL)QUINOLINE; 4 AMINOBUTYRIC ACID; AGMATINE; ALCOHOL; CAFFEINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FENCLONINE; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; KETAMINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N(G),N(G) DIMETHYLARGININE; NALOXONE; NEUROTRANSMITTER; NICOTINE; NITRIC OXIDE; PAROXETINE; PHENCYCLIDINE; PSYCHOSTIMULANT AGENT; PUTRESCINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SPERMIDINE; SPERMINE; STREPTOZOCIN; UNINDEXED DRUG;

ANALGESIA; ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASES; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC SYSTEM; HABITUATION; HISTOPATHOLOGY; HUMAN; LOCOMOTION; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PREPULSE INHIBITION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY; TREATMENT INDICATION;

AGMATINE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; SCHIZOPHRENIA;

EID: 84870405482     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803530601     Document Type: Article

References (73)

1. nd ed.; Cambridge University Press: Cambridge, 2000.
2. Tabor, C.W.; Tabor, H. Polyamines. Annu. Rev. Biochem., 1984, 53, 749-790.
3. Petroff, O.A.C. GABA and glutamate in the human brain. Neuroscientist, 2002, 8, 562-573.
4. Kossel, A. Über das Agmatin. Zeitschrift für Physiologische Chemie, 1910, 66, 257-261.
5. Reis, D.J.; Regunathan, S. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol. Sci., 2000, 21, 187-193.
6. Reis, D.J.; Regunathan, S. Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann N Y Acad Sci, 1999, 881, 65-80.
7. Otake, K.; Ruggiero, D.A.; Regunathan, S.; Wang, H.; Milner, T.A.; Reis, D.J. Regional localization of agmatine in the rat brain: An Immunocytochemical study. Brain Res., 1998, 787, 1-14.
8. Regunathan, S. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. J. Pharmacol. Exp. Ther., 1996, 276, 1272-1282.
9. Kuzirian, A.; Meyhöfer, E.; Hill, L.; Neary, J.T.; Alkon, DL. Autoradiographic measurement of tritiated agmatine as an indicator of physiologic activity in Hermissenda visual and vestibular neurons. J. Neurocytol., 1986, 15, 629-643.
10. Molderings, G.J.; Schmidt, K.; Bönisch, H.; Göthert, M. Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites. Naunyn Schmiedebergs Arch. Pharmacol., 1996, 354, 245-52.
11. Yang, K.C.; Reis, D.J. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J. Pharmacol. Exp. Ther., 1999, 288, 544-549.
12. Galea, E.; Regunathan, S.; Eliopoulos, V.; Feinstein, D.L.; Reis, D.J. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem. J., 1996, 316(pt 1), 247-249.
13. Uzbay, I.T.; Oglesby, M.W. Nitric oxide and substance dependence. Neurosci. Biobehav. Rev., 2001, 25, 43-52.
14. Sastre, M.; Regunathan S.; Reis, D.J. Uptake of agmatine into rat brain synaptosomes: Possible role of cation channels. J. Neurochem., 1997, 2421-2425.
15. Reis, D.J.; Regunathan, S. Agmatine: a novel neurotransmitter? Adv. Pharmacol., 1998, 42, 645-649.
16. Uzbay, T.I. The pharmacological importance of agmatine in brain. Neurosci. Biobehav. Rev., 2012, 36, 502-519.
17. Regunathan, S. Agmatine: Biological role and therapeutic potentials in morphine analgesia and dependence. The AAPS Journal, 2006, 8, E479-E484.
18. Karadag, H.C.; Ulugol, A.; Tamer, M.; Ipci, Y.; Dokmeci, I. Systemic agmatine attenuates tactile allodynia in two experimental neuropathic pain models in rats. Neurosci. Lett., 2003, 339, 88-90.
19. Aggarwal, S.; Shavalian, B.; Kim, E.; Rawls, S.M. Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception. Pharmacol. Biochem. Behav., 2009, 93, 426-432.
20. Bence, A.K.; Worthen, D.R.; Stables, J.P.; Crooks, P.A. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol. Biochem. Behav., 2003, 74, 771-775.
21. Feng, Y.; LeBlanc, M.H.; Regunathan, S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Nerosci. Lett., 2005, 390, 129-133.
22. Lavinsky, D.; Sarmento, N.; Carlos, A.; Netto, A. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav. Brain Res., 2003, 141, 19-24.
23. Zomkowski, A.D.E.; Santos, A.D.R.; Rodrigues, A.L.S. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci. Lett., 2005, 381, 279-283.
24. Zeidan, M.P.; Zomkowski, A.D.; Rosa, A.O.; Rodrigues, A.L.; Gabilan, N.H. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur. J. Pharmacol., 2007, 565, 125-131.
25. Krass, M.; Wegener, G.; Vasar, E.; Volke, V. Antidepressant-like effect of agmatine is not mediated by serotonin. Behav. Brain Res., 2008, 188, 324-328.
26. Taksande, B.G.; Kotagale, N.R.; Tripathi, S.J.; Ugale, R.R.; Chopde CT. Antidepressant-like effect of selective serotonin reuptake inhibitorsinvolve modulation of imidazoline receptors by agmatine. Neuropharmacology, 2009, 57, 415-424.
27. Halaris, A.; Zhu, H.; Feng, Y.; Piletz, J.E. Plasma agmatine and platelet imidazoline receptors in depression. Ann. N. Y. Acad. Sci., 1999, 881, 445-51.
28. Yesilyurt, O.; Uzbay, I.T. Agmatine potentiates the analgesic effect of morphine by an α2-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology, 2001, 25, 98-103.
29. 2 receptor ligands. Eur. J. Pharmacol., 2011, 669, 59-65.
30. 2 receptor ligands on morphine- and tramadol-induced antinociception in rats. Eur. J. Pharmacol., 2011, 670, 435-440.
31. Bhutada, P.; Mundhada, Y.; Humane, V.; Rahigude, A.; Deshmukh, P.; Latad, S.; Jain, K.; Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 37, 9-105.
32. Kim, J.H.; Yenari, M.A.; Giffar, R.G.; Cho, S.W.; Park, K.A.; Lee, J.E. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp. Neurol., 2004, 189, 122-130.
33. Kuo, J-R.; Lo, C-J.; Chio, C-C.; Chang, C-P.; Lin, M-T. Resuscitation from experimental traumatic brain injury by agatine therapy. Resuscitation, 75, 2008, 506-514.
34. Aricioglu-Kartal, F.; Uzbay, I.T. Inhibitory effect of agmatine on naloxoneprecipitated abstinence syndrome in morphine dependent rats. Life Sci. 1997, 61, 1775-1781.
35. Uzbay, I.T.; Yesilyurt, O.; Celik, T.; Ergun, H.; Isimer, A. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav. Brain Res., 2000, 107, 153-159.
36. Uzbay, T.; Kose, A.; Kayir, H.; Ulusoy, G.; Celik, T. Sex-related effects of agmatine on caffeine-induced locomotor activity in Swiss Webster mice. Eur. J. Pharmacol., 2010, 630, 69-73.
37. Ozden, O.; Kayir, H.; Ozturk, Y.; Uzbay, I.T. Agmatine blocked ethanolinduced locomotor activity in mice. Eur. J. Pharmacol., 2011, 659, 26-29.
38. Kotagale, N.R.; Taksande, B.G.; Gahane, A.Y.; Ugale, R.R.; Chopde, C.T. Repeated agmatine treatment attenuates nicotine sensitization in mice: modulation by alpha2-adrenoceptors. Behav. Brain Res., 2010, 213, 161-174.
39. Taksende, B.G.; Kotagale, N.R.; Nakhate, K.T.; Mali, P.D.; Kokare, D.M.; Hirani, K.; Subhedar, N.K.; Chopde, C.T.; Ugale, R.R. Agmatine in the hypothalamic paraventricular nucleus stimulates feeding in rats: involvement of neuropeptide Y. Br. J. Pharmacol., 2011, 164, 704-718.
40. Uzbay, I.T. New pharmacological approaches to the treatment of schizophrenia. Turk. Psikiyatri Derg., 2009, 20, 175-182.
41. Abi-Dargham, A. Evidence from brain imaging studies for dopaminergic alterations in schizophrenia. In: Dopamine in the Pathophysiology and Treatment of Schizophrenia. Kapur, S.; Lecrubier, Y., Ed.; Talor and Francis: London and New York, 2005; pp. 15-47.
42. Stefan, M.; Travis, M.; Murray, R.M. An Atlas of Schizophrenia. The Parthenon Publishing Group: London, 2002.
43. Lahti, A.C.; Weiler, M.A.; Tamara Michaelidis, B.A.; Parwani, A.; Tamminga, C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology, 2001, 25, 455-467.
44. Konradi, C.; Heckers, S. Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry, 2001, 50, 729-742.
45. Frost, D.O.; Tamminga, C.A.; Medoff, D.R.; Caviness, V.; Innocenti, G.; Carpenter, W.T. Neuroplasticity and schizophrenia. Biol. Psychiatry, 2004, 56, 540-543.
46. Shoval, G.; Weizman, A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropharmacol, 2005, 15, 319-329.
47. Ramchand, C.N.; Das, I.; Gliddon, A.; Hirsch, S.R. Role of polyamines in the membrane pathology of schizophrenia. A study using fibroblasts from schizophrenic patients and normal controls. Schizophr. Res., 1994, 13, 249-254.
48. Lindsley, C.W.; Shipe, W.D. ; Wolkenberg, S.E. ; Theberge, C.R. ; Williams, D.L. Jr; Sur, C.; Kinney, G.G. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem., 2006, 6, 771-785.
49. Harrison, P.J. Metabotropic glutamate receptor agonists for schizophrenia. Br. J. Psychiatry, 2008, 192, 86-87.
50. Richardson-Andrews, R.C. A central role for the polyamines in the aetiology of schizophrenia. Med. Hypotheses, 1983, 11, 157-166.
51. Andrews, R.C. The side effects of antimalarial drugs indicate a polyamine involvement in both schizophrenia and depression. Med. Hypotheses, 1985, 18, 11-18.
52. Gilad, G.M.; Gilad, V.H.; Casanova, M.F.; Casero, R.A. Jr. Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Biol. Psychiatry, 1995, 38, 227-234.
53. Das, I.; Khan, N.S.; Puri, B.K.; Hirsch, S.R. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci. Lett., 1996, 215, 209-211.
54. Kopieczna-Grzebieniak, E.; Goss, M. The importance of regulation of endogenous methylarginine concentrations in clinical practice. Przegl. Lek., 2005, 62, 1494-1501.
55. Salum, C.; Guimarães, F.S.; Brandão, M.L.; Del Bel, E.A. Dopamine and nitric oxide interaction on the modulation of prepulse inhibition of the acoustic startle response in the Wistar rat. Psychopharmacology, 2006, 185, 133-141.
56. Geyer, M.A.; Braff, D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr. Bull., 1987, 13, 643-668.
57. Braff, D.L.; Swerdlow, N.R.; Geyer, M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry, 1999, 156, 596-602.
58. Perry, W.; Minassian, A.; Feifel, D.; Braff, D.L. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol. Psychiatry., 2001, 50, 418-424.
59. Carroll, C.A.; Vohs, J.L.; O'donnell, B.F.; Shekhar, A.; Hetrick, W.P. Sensorimotor gating in manic and mixed episode bipolar disorder. Bipolar Disord., 2007, 9, 221-229.
60. Swerdlow, N.R.; Geyer, M.A. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol. Biochem. Behav., 1993, 44, 741-744.
61. Varty, G.B.; Higgins, G.A. Examination of drug-induced and isolationinduced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology, 1995, 122, 15-26.
62. Uzbay, I.T.; Kayir, H.; Goktalay, G.; Yildirim, M. Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. J. Psychopharmacol., 2010, 24, 923-929.
63. Sampson, C., Zhang, Y., Del Bello, F., Li, J.X. Effects of imidazoline I2 receptor ligands on acute nociception in rats. 23, Neuroreport, 2012, 73-77.
64. Cui, H.; Lee, J.H.; Kim, J.Y.; Koo, B.N.; Lee, J.E. The neuroprotective effect of agmatine after focal cerebral ischemia in diabetic rats. J. Neurosurg. Anesthesiol., 2012, 24, 39-50.
65. Palsson, E.; Fejgin, K.; Wass, C.; Klamer, D. Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. Eur. J. Pharmacol., 2008, 590, 212-216.
66. Kotagale, N.R.; Taksande, B.G.; Wadhwani, P.J.; Palhade, M.W.; Mendhi, S.M.; Gawande, D.Y.; Hadole, P.N.; Chopde, C.T. Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. Pharmacol. Biochem. Behav., 2012, 100, 398-403.
67. Swerdlow, N.R.; Benbow, C.H.; Zisook, S.; Geyer, M.A.; Braff, D.L. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol. Psychiatry, 1993, 33, 298-301.
68. Ludewig, S.; Ludewig, K.; Geyer, M.A.; Hell, D.; Vollenweider, F.X. Prepulse inhibition deficits in patients with panic disorder. Depress. Anxiety, 2002, 15, 55-60.
69. Swerdlow, N.R.; Paulsen, J.; Braff, D.L.; Butters, N.; Geyer, M.A.; Swenson, M.R. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J. Neurol. Neurosurg. Psychiatry, 1995, 58, 192-200.
70. Castellanos, F.X.; Fine, E.J.; Kaysen, D.; Marsh, W.L.; Rapoport, J.L.; Hallett, M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol. Psychiatry, 1996, 39, 33-41.
71. Molderings, G.J.; Haenisch, B. Agmatine (decarboxylated l-arginine): Physiological role and therapeutic potential. Pharmacol Ther., 2012, 133, 351-365.
72. Keynan, O.; Mirovsky, Y.; Dekel, S.; Gilad, V.H.; Gilad, G.M. Safety and efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. An open-label, dose-escalating study followed by a randomized, doubleblind, placebo-controlled trial. Pain Med., 2010, 11, 356-368.
73. Laube, G.; Bernstein, H.G. Agmatine in the brain: An emerging "human" perspective. Neurosci. Biobehav. Rev., 2012, 36, 872, 2012.